CLINICAL TRIALS PROFILE FOR ORACEA

All Clinical Trials for ORACEA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00358462 ↗	Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2007-01-01	The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT00358462 ↗	Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)	Completed	University of Washington	Phase 3	2007-01-01	The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT00480532 ↗	A Study of Continuous Oral Contraceptives and Doxycycline	Completed	Oregon Health and Science University	N/A	2007-05-01	The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only contraception but has not been studied in combined hormonal contraception.
NCT00892281 ↗	ORCA - Oracea® for Rosacea: A Community-based Assessment	Completed	Galderma Laboratories, L.P.	Phase 4	2009-04-01	The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
NCT01308619 ↗	Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo	Completed	Galderma Laboratories, L.P.	Phase 4	2011-04-01	The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
NCT01426269 ↗	Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo	Completed	Galderma Laboratories, L.P.	Phase 4	2011-09-01	The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.

Clinical Trial Conditions for ORACEA

Condition Name

Condition Name for ORACEA
Intervention	Trials
Rosacea	4
Buruli Ulcer	1
Central Centrifugal Cicatricial Alopecia (CCCA)	1
Co-infection	1

Condition MeSH

Condition MeSH for ORACEA
Intervention	Trials
Rosacea	5
Tuberculosis	1
Aortic Aneurysm	1
Buruli Ulcer	1

Clinical Trial Locations for ORACEA

Trials by Country

Trials by Country for ORACEA
Location	Trials
United States	67
Canada	1
Ghana	1
Hungary	1

Trials by US State

Trials by US State for ORACEA
Location	Trials
Texas	5
California	5
Kentucky	5
Oregon	5
Florida	4

Clinical Trial Progress for ORACEA

Clinical Trial Phase

Clinical Trial Phase for ORACEA
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ORACEA
Clinical Trial Phase	Trials
Completed	12
Recruiting	1

Clinical Trial Sponsors for ORACEA

Sponsor Name

Sponsor Name for ORACEA
Sponsor	Trials
Galderma Laboratories, L.P.	4
Oregon Health and Science University	1
University of Bonn	1

Sponsor Type

Sponsor Type for ORACEA
Sponsor	Trials
Other	15
Industry	6
NIH	2

ORACEA (oracea/doxycycline hyclate 40 mg delayed-release) clinical trials update, market analysis, and exclusivity-to-launch projection

Last updated: May 21, 2026

Executive summary

• ORACEA is a once-daily doxycycline delayed-release 40 mg capsule indicated for inflammatory lesions of rosacea in adults. Its sales and competitive position depend on continued brand loyalty versus low-cost generics of doxycycline and on whether FDA exclusivities and listed patents restrict any non-authorized entry of the specific 40 mg delayed-release product.
• Clinical development activity for ORACEA is largely limited in scope because the product is an approved, reformulated-dose brand rather than a new chemical entity. Updates typically track new label expansions, comparative studies, and formulation or lifecycle work that do not reset core patent clocks.
• Market outlook hinges on (1) rosacea prevalence and prescribing intensity, (2) payor adoption versus generic doxycycline, and (3) any near-term generic entry risk tied to ANDA paragraph IV challenges for the 40 mg delayed-release formulation.

What is ORACEA (doxycycline hyclate delayed-release 40 mg) used for and what is the current FDA status?

ORACEA (doxycycline hyclate) delayed-release capsules 40 mg is used for inflammatory lesions of rosacea in adults. The product is positioned as an oral antibiotic with dose and formulation designed to reduce systemic exposure relative to older doxycycline regimens used for other indications.

Key regulatory framing

• Indication: inflammatory lesions of rosacea.
• Dose form: delayed-release oral capsule, 40 mg.
• FDA review posture: NDA brand, with any exclusivity and listed patent limitations shown in the Orange Book for the marketed dosage form and strength.

Featured snippet answer ORACEA is an FDA-approved, once-daily doxycycline hyclate delayed-release 40 mg capsule for adult inflammatory rosacea.

What clinical trials have been run for ORACEA and what is the latest update in the public record?

Public clinical-trials activity for ORACEA typically clusters around pivotal approval studies and post-approval lifecycle work that supports labeling, comparative pharmacology, or manufacturing changes rather than a new indication at late stage.

Pivotal and supporting study pattern (high level)

• Phase 3 program for inflammatory rosacea lesion reduction using once-daily delayed-release 40 mg.
• Supportive pharmacokinetic and dose-ranging work comparing systemic exposure to immediate-release doxycycline and addressing tolerability.
• Post-marketing or smaller studies addressing safety, adherence, and real-world consistency.

What to watch in “latest update” signals

• If new registrational trials are filed, they usually show up as protocol updates or new NCT entries related to rosacea subtype, comorbidities, or combination regimens.
• If no new NCT activity appears at late phase, “updates” often reflect completed recruitment status, results posted, or amendments to ongoing studies.

Where does ORACEA face clinical substitution risk versus other rosacea therapies?

The competitive set for inflammatory rosacea includes:

• Topical agents (azelaic acid, ivermectin, metronidazole, and others).
• Anti-inflammatory and anti-microbial class alternatives.
• Laser and procedural therapies.
• Oral doxycycline immediate-release regimens and other antibiotics used off-label or through older label pathways.

Substitution pressure

• ORACEA’s differentiation is the delayed-release 40 mg regimen aimed at sustained efficacy with a tolerability profile distinct from higher-dose doxycycline.
• Generic immediate-release doxycycline can compete on price even if the formulation differs, depending on prescriber switching patterns and patient out-of-pocket costs.

What patents protect ORACEA and how strong is the patent estate for the 40 mg delayed-release rosacea product?

ORACEA is protected by an FDA-listed patent estate that can include:

• Composition-of-matter for doxycycline-related subject matter (where applicable).
• Formulation and dosage form patents for delayed-release properties at 40 mg.
• Method-of-use patents tied to treating rosacea inflammatory lesions with the specific regimen.

Patent estate strength signals

• If the remaining listed patents include formulation and method-of-use claims tied tightly to delayed-release doxycycline at 40 mg, ANDA entry for an exact product match can face more risk.
• If the remaining claims are narrow and expire earlier, generic entry can occur for non-infringing or design-around products.

When does ORACEA lose exclusivity, and what are the key expiration dates for exclusivity and listed patents?

Exclusivity and patent loss for ORACEA are determined by:

1. FDA Orange Book listed patents (expirations and, where applicable, pediatric exclusivity extensions).
2. Any exclusivity granted under the NDA pathway (data exclusivity periods and other statutory exclusivities).

Featured snippet answer ORACEA’s exclusivity and patent-driven exclusivity timeline is defined by the Orange Book listed patents and any pediatric extensions on those patents for the delayed-release 40 mg capsule.

What is the Orange Book status of ORACEA (listed patents, patent owners, and expiration framework)?

The Orange Book provides:

• Patent numbers listed for ORACEA’s marketed dosage form.
• Assignees (patent holders).
• Patent type (composition, formulation, method of use).
• Expiration dates by patent.

Market-access relevance

• A patent that expires later than any other listed patents can drive the earliest legally permitted generic entry even if another component expires.

How many Paragraph IV challenges could affect ORACEA, and what does the litigation profile look like?

Paragraph IV filings typically align with:

• ANDA submissions by generic applicants asserting non-infringement or invalidity of Orange Book patents.
• Litigation between the brand and challenger.

What the litigation profile indicates

• Multiple Paragraph IVs at once can indicate perceived “patent thinning,” design-around feasibility, or timing-driven generic strategies.
• Early dismissals or settlements can reduce launch uncertainty but also often create a negotiated “authorized generic” or entry window.

Which companies are challenging ORACEA, and what are the settlement or consent decree terms that control launch?

Generic applicants typically negotiate:

• “Carve-out” design-around formulations.
• Entry dates tied to patent expiry.
• License or supply agreements where allowed.

Launch-control relevance

• Settlements can set de facto launch dates even when patents remain on paper.
• Consent decrees can lock entry while appeals progress.

How strong is ORACEA’s competitive position versus generic doxycycline and other rosacea brands?

Competitive drivers:

• Total cost of therapy for patients and payors.
• Formulation-level differentiation: delayed-release vs immediate-release substitution.
• Prescriber familiarity and clinical preference for the rosacea-specific delayed-release regimen.

Price dynamics

• Generic doxycycline can undercut ORACEA on acquisition cost.
• ORACEA can maintain share if payors cover it at attractive net pricing or if clinicians view delayed-release as clinically meaningful.

What generic entry risks exist for ORACEA (ANDA design-around, authorized generics, and timing scenarios)?

Generic entry risk depends on how challengers can:

• Deliver a product with the same or similar delayed-release profile at 40 mg.
• Avoid infringement of formulation or method-of-use claims.
• Enter “at risk” if litigation is unresolved.

Launch scenarios (framework)

• Best case for generics: early patent expiry or successful invalidation and faster litigation resolution.
• Base case: entry on an Orange Book earliest-expiration date or after a settlement-triggered date.
• Worst case: injunction risk, settlement delays, or redesign around claims that postpones effective launch.

What formulations are protected for ORACEA, and do delayed-release claims block alternative doxycycline dosing?

Patent coverage often targets:

• Delayed-release coating and release profile that supports tolerability and consistent exposure.
• Specific dosage form design for 40 mg daily.
• Use in rosacea patient populations under particular treatment paradigms.

Substitution implications

• If patents are specific to the 40 mg delayed-release capsule regimen, a different dose (for example 20 mg or immediate-release) could face a lower IP barrier depending on claim scope.

How does ORACEA compare with competing rosacea oral antibiotics in terms of efficacy, dosing, and switching?

At a strategy level, ORACEA’s differentiation is:

• 40 mg delayed-release daily dosing rather than higher-dose regimens.
• Prescriber preference for a rosacea-labeled regimen when available.

Competitors may include:

• Lower-dose doxycycline options (if formulation and release match protected claims).
• Non-doxycycline oral therapies for rosacea if label-appropriate in a given geography.

What is ORACEA’s market size, revenue trajectory, and share drivers by geography?

Market analysis for ORACEA typically requires:

• U.S. prescription volume for rosacea inflammatory lesion regimens.
• Average net price trends affected by rebates and generic substitution.
• Geographic expansion status and local formulary inclusion.

Projection logic used in market modeling

• Rosacea prevalence and diagnosis rates.
• Treatment adherence and persistence for once-daily regimens.
• Competitive switching once generics or therapeutically substitutable agents gain payer coverage.

What is the projection for ORACEA through the next patent and exclusivity windows?

A credible projection is driven by:

• Patent expiry calendar mapped to ANDA launch timelines.
• Litigation and settlement schedules that determine when generic competition begins to hit net price.
• Payor contracting behavior and substitution policy.

Scenario-based forecast structure

• Pre-generic ramp: steady brand volume with gradual discounting or increased promotion.
• On-launch: step-down in net pricing and share if generic delayed-release is substitutable by formulary policy.
• Post-launch: share stabilization at a lower “branded premium” level depending on whether delayed-release exclusivity is maintained.

What risks and opportunities could change the ORACEA outlook (new trials, label changes, or new generics)?

Key swing factors:

• Any label change that expands use could add new volume but typically does not erase formulation-specific patent timelines.
• Any additional Orange Book patent listing can extend the brand’s legal runway if properly listed and enforceable.
• Litigation outcomes or settlement-triggered dates often dominate near-term market access.

---

Key Takeaways

• ORACEA’s near-term business outlook depends primarily on Orange Book patent expiry and any Paragraph IV-and-settlement outcomes that control generic delayed-release 40 mg entry.
• Competitive substitution is a function of delayed-release differentiation versus payer-driven generic switching to doxycycline immediate-release or other rosacea therapies.
• Clinical “updates” in the public domain for ORACEA are likely lifecycle-level unless new registrational trials are initiated for an expanded indication or combination regimen.

FAQs

1. What are the most common ANDA design-around strategies for delayed-release doxycycline products like ORACEA?
2. Do method-of-use claims for rosacea treatments block generics that market the same delayed-release dose for rosacea?
3. How do settlements in Paragraph IV doxycycline rosacea cases typically define entry dates in the U.S.?
4. What payer formulary levers most influence whether patients switch from ORACEA to generic doxycycline?
5. How does delayed-release formulation affect pharmacokinetics in doxycycline rosacea regimens, and how does that map to patent infringement risk?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. FDA. Drug Approval Reports (NDA approval documents for ORACEA).
3. ClinicalTrials.gov. ORACEA (doxycycline hyclate delayed-release) related clinical studies and results postings.